Taipei Medical University

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Wu TC
------>authors3_c=???
------>paper_class1=1
------>Impact_Factor=5.440
------>paper_class3=2
------>paper_class2=1
------>vol=43
------>confirm_bywho=tlc
------>insert_bywho=g870905
------>Jurnal_Rank=11.8
------>authors4_c=???
------>comm_author=
------>patent_EDate=None
------>authors5_c=???
------>publish_day=1
------>paper_class2Letter=None
------>page2=1522
------>medlineContent=
------>unit=E0121
------>insert_date=20080421
------>iam=5
------>update_date=None
------>author=???
------>change_event=4
------>ISSN=
------>authors_c=???
------>score=500
------>journal_name=Free Radic Biol Med.
------>paper_name=Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis.
------>confirm_date=20080421
------>tch_id=096034
------>pmid=17964422
------>page1=1508
------>fullAbstract=Matrix metalloproteinase (MMP) is critical to the progression of atherosclerosis and neointima hyperplasia after vascular injury. We investigated the effects of carvedilol, a pharmacological antioxidant with alpha- and beta-adrenergic blocking activity, on MMP-2 and MMP-9 expression. Vascular injury was induced with the balloon catheters on abdominal aortas of high-cholesterol-fed rabbits. On Day 21, there was significant aortic neointima formation with increased oxidative DNA damage by immunostaining with 8-hydroxy-2~-deoxyguanosine and enhanced MMP-2 and MMP-9 expressions by Western blotting, which were significantly reduced by oral administration of carvedilol (20 mg/kg/day) or probucol (100 mg/kg/day). Vascular expression (by Western blot), activity (by gelatin zymography), and mRNA levels of MMP-2 and MMP-9 were also reduced by carvedilol or probucol. Besides, pretreatment with carvedilol or probucol but not propranolol, a beta-blocker, or prazocin, an alpha-blocker, inhibited tumor necrosis factor-alpha-stimulated expressions and activities of MMP-2 and MMP-9 in human aortic smooth muscle cells. On electrophoretic mobility-shift assay, carvedilol inhibited the binding activities of activator protein-1 and specific protein-1, two major transcription factors for MMP promoter regions. Accordingly, carvedilol, a pharmacological antioxidant, inhibited in vivo and in vitro expression of MMP-2 and MMP-9 properly by modulating the redox-related pathways, suggesting its potential clinical implications.
------>tmu_sno=None
------>sno=17804
------>authors2=Chen YH
------>authors3=Leu HB
------>authors4=Chen YL
------>authors5=Lin FY
------>authors6=Lin SJ, Chen JW
------>authors6_c=???, ???
------>authors=Wu TC
------>delete_flag=0
------>SCI_JNo=None
------>authors2_c=???
------>publish_area=0
------>updateTitle=Carvedilol, a pharmacological antioxidant, inhibits neointimal matrix metalloproteinase-2 and -9 in experimental atherosclerosis.
------>language=2
------>check_flag=None
------>submit_date=None
------>country=None
------>no=
------>patent_SDate=None
------>update_bywho=None
------>publish_year=2007
------>submit_flag=None
------>publish_month=8
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z